Wells Fargo raised the firm’s price target on Abbott (ABT) to $147 from $136 and keeps an Overweight rating on the shares. The firm notes the company reported a Q1 EPS beat despite Dx softness. Abbott maintained 2025 guide, which now includes a few hundred-million-dollar tariff impact starting in the second half of the year. Management believes through mitigation the annualized impact would be less than 2 times this, Wells adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $159 from $158 at Barclays
- Abbott Laboratories Reports Strong Q1 2025 Results
- Abbott Laboratories: Strong Buy Rating Amid Robust Financial Performance and Growth Potential
- Abbott price target raised to $137 from $135 at Jefferies
- Nvidia, AMD see charges due to new China export rules: Morning Buzz